Últimas noticias sobre bluebird bio (NASDAQ:BLUE) Bolsa

bluebird bio

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.

bluebird bio Inc

BLUE HOLDINGS INC by Blue Holdings, Inc.

BLUE WORLD ACQUISITION CORP USD RTS

BLUERIVER ACQUISITION CORP CL A ORD SHS

BLUESCAPE OPPORTUNITIES ACQUISITION CORP CL A

Blue Apron Holdings Inc COM PAR $

Blue Biofuels Inc

Blue Bird Corp

Blue Capital Reinsurance Holdings Ltd

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

BLUE DOLPHIN ENERGY CO by Blue Dolphin Energy Co.

Blue Dolphin Energy Co

BLUE EARTH RES INC by Blue Earth Resources, Inc.

Blue Earth Resources Inc

Blue Energy Ltd

Blue Foundry Bancorp

BLUE GEM ENTERPRISE by Blue Gem Enterprise

Blue Gem Enterprise

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive Entertainment Technology

CANOPUS BIOPHARMA INC by Canopus Biopharma, Inc.

Blue Heaven Coffee Inc

BLUE HORIZON GLOBAL CAP by BLUE HORIZON GLOBAL CAP CORP.

Blue Horizon Global Capital Corp

BLUE LAGOON RESOURCES INC by Blue Lagoon Resources Inc.

Blue Lagoon Resources Inc

BLUE LINE PROTECTION GRP by Blue Line Protection Group, Inc.

Blue Line Protection Group Inc

BLUE MOON GRP UNSP/ADR by Blue Moon Group Holdings Limited

Blue Moon Group Holdings Ltd

BLUE MOON METALS INC NEW by BLUE MOON METALS INC.

Blue Moon Metals Inc

BLUE NOTE MINING INC NEW by Blue Note Mining Inc.

Blue Note Mining Inc

Blue Ocean Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Blue Ocean Acquisition Corp

Blue Ocean Acquisition Corp Warrants (02/12/2026)

Blue Ocean Acquisition Corp Ordinary Shares - Class A

Blue Owl Capital Corporation Common Stock

Blue Owl Capital Corp

Blue Owl Capital Inc. Class A Common Stock

Blue Owl Capital Inc

Blue Ribbon Income Fund

Blue Ridge Bankshares Inc

BLUE RIDGE REAL ESTATE CO by Blue Ridge Real Estate Co.

Blue Ridge Real Estate Co

BLUE RIVER RES LTD ORD by Blue River Resources, Ltd.

Blue River Resources Ltd

BLUE SKY URANIUM CORP by Blue Sky Uranium Corp.

Blue Sky Uranium Corp

Blue Sphere Corp

BLUE STAR FOODS CORP by BLUE STAR FOODS CORP.

Blue Star Foods Corp

BLUE STAR GLOBAL INC by Blue Star Global, Inc.

Blue Star Global Inc

BLUE STAR GOLD CORP by Blue Star Gold Corp.

Blue Star Gold Corp

BLUE STAR HELIUM LTD by Blue Star Helium Ltd.

Blue Star Helium Ltd

BLUE STAR OPPTYS CORP by Blue Star Opportunities Corp.

Blue Star Opportunities Corp

BLUE WATER GLOBAL GRP INC by Blue Water Global Group, Inc.

Blue Water Global Group Inc

BLUE WATER PETROLEUM CP by Blue Water Petroleum Corp.

Blue Water Petroleum Corp

BLUE WATER VENTURES INC by Blue Water Ventures International, Inc.

Blue Water Ventures International Inc

Blue World Acquisition Corp Warrants (10/01/2029)

Blue World Acquisition Corp

Blue World Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

BLUEFIRE EQUIPMENT CORP by BlueFire Equipment Corp.

BlueFire Equipment Corp

BLUEHARBOR BANK (NC) by BlueHarbor Bank (Mooresville NC)

BlueHarbor Bank

BlueLinx Holdings Inc

BLUERIVER ACQ CORP A by BlueRiver Acquisition Corp.

BlueRiver Acquisition Corp

BlueRiver Acquisition Corp Warrants (04/01/2026)

BlueRiver Acquisition Corp Units (1 Ord Share Class A & 1/3 War)

BlueRush Inc

BLUESCOPE STEEL LTD by Bluescope Steel, Ltd.

BlueScope Steel Ltd

BLUESCOPE STL UNS/ADR NEW by Bluescope Steel, Ltd.

BLUEBERRIES MEDICAL CO by Blueberries Medical Co.

Blueberries Medical Corp

Bluegreen Vacations Holding Corp Class B

Bluegreen Vacations Holdings Corp Com Cl A

Bluejay Diagnostics Inc

Blueone Card Inc

Blueprint Chesapeake Multi-Asset Trend ETF

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

BLUEPRINT TECHS INC by Blueprint Technologies, Inc.

Blueprint Technologies Inc

Bluerock Homes Trust, Inc. Class A Common Stock

Bluerock Homes Trust Inc

BLUESKY DIGITAL ASSET CRP by Bluesky Digital Assets Corp.

Bluesky Digital Assets Corp

BLUESTEM GROUP INC by Bluestem Group Inc.

Bluestem Group Inc

Bluestone Resources Inc

These past three months were not what U.S. <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">dealmakers wanted or expected</a>.
As of April 3, transaction tracker Dealogic showed zero percent growth in U.S.-based M&amp;A volume compared to last year&#8217;s first quarter.
Elsewhere? Volume is spiking triple digits.
<ul>
<li>The Middle East and Africa combined are seeing 123% growth in M&amp;A.</li>
<li>Japan: 105%</li>
<li>Asia: 103%</li>
</ul>
Deal volume is also up in Canada, Europe and Australia. Only in Latin America is it in the red, with <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/03/44342234/deal-dispatch-trump-ma-boom-is-a-bust-purple-mattress-considers-sale-celtics-auction-heats-up">barely a peep</a> coming from the U.S.
For those keeping track of who correctly predicted this downtrend, don&#8217;t look to Bank of America. After Election Day, the firm&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">analysts boldly predicted</a> that the then-incoming Trump administration would remove Federal Trade Commission chair Lina Khan and, presto, the antitrust roadblocks for M&amp;A activity would be removed.
Those analysts were wrong. Just 10 days after Trump&#8217;s inauguration, the U.S. Department of Justice <a href="https://www.benzinga.com/news/legal/25/01/43353124/hewlett-packard-enterprise-shares-fall-as-us-department-of-justice-sues-to-block-juniper-acquisition">sued to block</a> Hewlett Packard Enterprise&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) $14 billion deal to acquire networking gear maker Juniper Networks. In March, Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) <a href="https://julian-34159.medium.com/m-a-malaise-whats-behind-the-2025-deal-slowdown-8471a15b914c">saw its stock price fall</a> after the FTC challenged a proposed acquisition by private equity firm GTCR LLC.
Those BofA analysts also forgot that the previous Trump administration was not particularly lenient regarding consolidation. AT&amp;T and Time Warner; Sinclair and Tribune Media; Broadcom and Qualcomm; DraftKings and FanDuel — <a href="https://www.benzinga.com/news/asset-sales/25/03/44202239/deal-dispatch-tiktok-walgreens-raizen">all blocked</a>.
On the shiny side, gold-related M&amp;A deals have increased, but transaction sizes are much smaller, Benzinga&#8217;s Stjepan Kalinic <a href="https://www.benzinga.com/news/legal/25/03/44490949/gold-ma-deals-are-accelerating-but-average-deals-are-smaller-research-shows">wrote this week</a>.
See Also: <a href="https://www.benzinga.com/government/regulations/25/04/44648681/powell-cites-tariff-driven-inflation-risks-shrugs-off-trumps-call-for-perfect-time-to-cut-rates">Trump Urges Immediate Rate Cuts, Powell Says It&#8217;s &#8216;Too Soon&#8217; As Tariffs Will Likely Drive Inflation</a>
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>I Squared Capital is considering selling its European trailer-leasing business, TIP Group, which could be valued at over €3 billion ($3.2 billion). The Miami-based firm is consulting advisers but has not yet launched a formal sale process, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-04-02/i-squared-said-to-weigh-3-billion-sale-of-trailer-leasing-firm?srnd=phx-deals&amp;sref=TBDibEcD">reports</a>. Based in Amsterdam, TIP Group may attract interest from infrastructure funds and industry peers. I Squared acquired the company in 2018 from HNA Group and has since expanded it through acquisitions, including Trailer Wizards in Canada and Eurotrail UK Ltd. The company was rebranded as TIP Group in 2022.</li>
</ul>
<ul>
<li>Bowmark Capital is working with Arma Partners on a potential sale of workforce management software firm Totalmobile, which could be valued at over £500 million ($649 million). A formal sale process may start later this year, according <a href="https://www.bloomberg.com/news/articles/2025-04-02/pe-firm-bowmark-said-to-weigh-500-million-sale-of-totalmobile?sref=TBDibEcD">to</a> Bloomberg. Totalmobile, which provides field service management software, could attract interest from private equity firms and industry players. Bowmark acquired the company in 2020, and deliberations on the sale are still in the early stages.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Final bids for Eni SpA&#8216;s 15% stake in Plenitude, a renewables company, are expected in the coming weeks. Apollo Global Management, Ares Management and Stonepeak are among the interested parties, according to Bloomberg—initial interest values Plenitude between €12 billion and €13 billion ($14 billion).</li>
</ul>
<ul>
<li>Ayrmid Ltd. <a href="https://www.benzinga.com/25/03/44564776?57575">offered to acquire</a> Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) for an upfront cash payment of $4.50 per share. The company topped a $3.00 per share bid from private equity firms <a href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal">Carlyle and SK Capital Partners</a>.</li>
</ul>
<ul>
<li>Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44565671/rocket-acquires-mr-cooper-just-weeks-after-buying-redfin-brings-together-the-homeownership-experience-at-scale">announced it will acquire</a> Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) in an all-stock transaction for $9.4 billion in equity value. The move comes just after Rocket's $1.75 billion acquisition of <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44237879/rocket-redfin-deal-aims-to-create-end-to-end-real-estate-solution-where-does-that-leave-zillow">online real estate broker Redfin Corp. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>).&nbsp;</li>
</ul>
<ul>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) <a href="https://www.benzinga.com/25/04/44643347/hershey-expands-snack-empire-with-acquisition-of-lesserevil-for-750m">agreed to acquire</a> snack brand LesserEvil. This move reflects the confectionery giant&#8217;s ongoing effort to expand from sweets such as Reese&#8217;s and Jolly Ranchers into the better-for-you snack sector. The acquisition is <a href="https://www.wsj.com/business/deals/hershey-nears-750-million-deal-for-lesserevil-popcorn-brand-4ca3d468?mod=lead_feature_below_a_pos1" target="_blank" rel="noreferrer noopener">reportedly</a> valued at around $750 million.</li>
</ul>
<ul>
<li>Rogers Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) said on Friday it agreed to receive a 7 billion Canadian dollar (~$5 billion) equity investment from funds managed by Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), supported by <a href="https://www.benzinga.com/news/asset-sales/25/04/44646240/rogers-scores-5-billion-blackstone-deal-to-cut-debt-unlock-wireless-infrastructure-value">several Canadian institutional investors</a>.</li>
</ul>
<ul>
<li>President Trump confirmed that the U.S. is <a href="https://in.benzinga.com/general/social-media/25/02/43511395/trump-pushes-for-tiktok-deal-china-could-oblige-if-it-werent-for-those-tariffs-heres-what-we-know" target="_blank" rel="noreferrer noopener">nearing a deal</a> to spare TikTok from a potential ban, with ongoing discussions involving multiple investors and a possible tariff agreement with China. During <a href="https://www.benzinga.com/25/04/44641024/trump-says-us-close-to-tiktok-deal-reiterates-his-offer-of-tariff-relief-to-secure-chinas-consent-the-tariffs-give-us-great-power-to-negotiate">remarks aboard</a> Air Force One, Trump didn&#8217;t specify whether the &#8220;very good group of people&#8221; interested in TikTok includes OnlyFans founder Tim Stokely. AppLovin and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44645102/applovin-wants-tiktok-but-can-it-beat-amazon-and-onlyfans-to-the-punch">also reportedly interested</a>.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>Hooters, the restaurant chain known for its all-female waitstaff and neon orange branding, <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">officially filed for bankruptcy protection</a>. The Chapter 11 filing allows the chain to continue normal operations during the proceeding. Hooters said that all of its 100 restaurants will be sold to two existing franchisees, which own and operate more than 30% of Hooters&#8217; locations in the U.S.</li>
</ul>
For the previous edition of <a href="https://www.benzinga.com/news/25/03/44546940/deal-dispatch-bezos-backed-crop-company-wilts-tech-startup-nabs-napster-for-207-million">Deal Dispatch, click here</a>.

News

Politics

AMZN

BLUE

COOP

RDFN

SHEL

SRDX

Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking

Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares are trading higher Monday after the company received an unsolicited takeover <a href="https://www.benzinga.com/25/03/44564776/gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps">offer from Ayrmid Ltd</a>.
What To Know: The offer includes an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of net sales milestones.
The bid comes after Bluebird had already agreed in February to be acquired and taken private by Carlyle and SK Capital Partners for $3 per share in cash, with the same $6.84 contingent value right. 
Bluebird said it previously reviewed strategic alternatives and even engaged in discussions with Ayrmid, but Ayrmid did not submit a proposal at that time. The company's board is now reviewing the new offer with legal and financial advisors. Investors appear to be reacting to the possibility of a higher takeover price.
Bluebird Bio shares are also getting a boost from Barclays on Monday after the analyst firm maintained an <a href="https://www.benzinga.com/analyst-stock-ratings">Overweight rating</a> and set a price target of $8.
Blue Price Action: BlueBird Bio shares were up 24.1% at $5.06 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png" alt="" class="wp-image-849883" style="width:388px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31151817/Screenshot-2025-03-31-at-15.17.57.png 1494w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/03/44567966/stocks-fall-sp-500-eyes-worst-month-in-almost-two-years-oil-rallies-whats-driving-markets-monday">Stocks Fall, S&amp;P 500 Eyes Worst Month In Almost Two Years, Oil Rallies: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Image Via Shutterstock.

Movers

BlueBird Shares Are Up Today: What's Going On?

WIIM

BlueBird Bio shares are trading higher after the company received a non-binding written takeover proposal from Ayrmid. Also, Barclays maintained its Overweight rating on the stock.

<h3>Gainers</h3>
<ul>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock moved upwards by 88.8% to $103.12 during Monday's regular session. The market value of their outstanding shares is at $10.8 billion. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 38.2% to $35.48. The company's market cap stands at $461.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 34.34% to $0.89. The market value of their outstanding shares is at $63.9 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares rose 26.41% to $5.16. The market value of their outstanding shares is at $50.2 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) shares moved upwards by 13.95% to $0.57. The company's market cap stands at $8.3 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock rose 13.34% to $0.97. The market value of their outstanding shares is at $23.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares declined by 46.9% to $36.92 during Monday's regular session. The company's market cap stands at $4.7 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 34.87% to $0.99. The market value of their outstanding shares is at $11.3 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 30.87% to $0.65. The company's market cap stands at $3.4 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares fell 30.06% to $1.35. The market value of their outstanding shares is at $276.7 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 27.49% to $0.35. The market value of their outstanding shares is at $1.5 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares decreased by 23.08% to $11.17. The market value of their outstanding shares is at $166.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

CORT

CTOR

NGNE

NIVF

PCVX

PLRZ

TSHA

12 Health Care Stocks Moving In Monday's Intraday Session

Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Ayrmid has proposed to acquire Bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achieving a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44545777/bluebird-bio-confirms-receipt-of-an-unsolicited-non-binding-proposal-from-ayrmid" rel="noreferrer noopener">net sales milestone</a>.
In February 2025, Bluebird entered into a definitive agreement with Carlyle and SK Capital Partners to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a <a target="_blank" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal" rel="noreferrer noopener">net sales milestone</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a>
Bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives.
Ayrmid did not submit any proposal to Bluebird during that process.
Consistent with its fiduciary duties, the Bluebird Board of Directors is reviewing the Ayrmid Proposal in consultation with its legal and financial advisors.
In November 2024, the FDA raised concerns about life-threatening hematologic malignancies in patients treated with Bluebird Bio&#8217;s Skysona (elivaldogene autotemcel), a gene therapy for early, active cerebral <a href="https://www.benzinga.com/general/biotech/24/11/42243241/fda-probes-potential-life-threatening-blood-cancer-risks-linked-to-bluebird-bios-skysona-gene-therapy" target="_blank" rel="noreferrer noopener">adrenoleukodystrophy (CALD)</a>.
The agency has received reports of myelodysplastic syndrome and acute myeloid leukemia linked to Skysona, with cases emerging 14 to 92 months post-treatment during clinical trials.
Price Action: BLUE stock is up 7.84% at $4.40 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544574/eye-care-topcon-goes-private-via-management-buyout-deal-of-around-22-per-share" target="_blank" rel="noreferrer noopener">Eye Care Company Topcon Goes Private Via Management Buyout Deal At Huge Premium</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Trading Ideas

General

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Overweight and lowers the price target from $40 to $8.

Price Target

Analyst Ratings

Barclays Maintains Overweight on bluebird bio, Lowers Price Target to $8

QSG: 50% &#x7C; <a href="https://www.benzinga.com//node/44453294">QuantaSing Group Expands Into Pop Toys Market with Strategic Acquisition Of Letsvan, Tapping High-Growth Consumer Goods Segment</a>
&nbsp;
BLUE: 30% &#x7C; <a href="https://www.benzinga.com//node/44545983">Bluebird Bio shares are trading higher after the company confirmed it received an unsolicited non-binding proposal from Ayrmid.</a>

Market-Moving News for March 31st

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 11.9% to $0.75 during Friday's after-market session. The company's market cap stands at $108.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 10.96% to $0.81. The market value of their outstanding shares is at $2.2 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 10.0% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock increased by 9.8% to $4.48. The company's market cap stands at $43.6 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares increased by 9.75% to $4.5. The market value of their outstanding shares is at $165.9 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares rose 8.89% to $0.56. The market value of their outstanding shares is at $48.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 20.5% to $0.02 during Friday's after-market session. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 16.83% to $0.17. The market value of their outstanding shares is at $2.2 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock decreased by 14.57% to $0.52. The market value of their outstanding shares is at $13.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares decreased by 14.26% to $0.37. The market value of their outstanding shares is at $19.3 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock decreased by 13.39% to $3.3. The company's market cap stands at $2.4 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 11.95% to $0.06. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

GCTK

GELS

IPSC

LGMK

MOLN

OCEA

Qualigen Therapeutics, Inc. - Common Stock

QLGN

12 Health Care Stocks Moving In Friday's After-Market Session

Bluebird Bio shares are trading higher after the company confirmed it received an unsolicited non-binding proposal from Ayrmid.

bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.
As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the "Merger Agreement") with funds managed by global investment firms Carlyle and SK Capital Partners, LP to be acquired and taken private for $3.00 per share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone, contingent upon certain offer conditions (the "Merger"). bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives. Ayrmid did not submit any proposal to bluebird as part of that process. The Ayrmid Proposal is subject to certain conditions and further negotiations between the parties, including confirmatory diligence.

bluebird bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid To Acquire Bluebird For An Upfront Cash Payment Of $4.50 Per Share And A One-Time Contingent Value Right Of $6.84 Per Share Payable Upon Achievement Of A Net Sales Milestone

<a href="https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/" title="https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/">https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/</a>

'Bluebird Gets New M&A Bid, Seeking To Top Private Equity Offer' - Endpoints News

Rumors

Watching bluebird bio; Traders Circulate Unconfirmed M&A Blog Comments Suggesting The Co Gets New M&A Bid, Seeking To Top Private Equity Offer

On Monday, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) agreed to acquire 2seventy bio, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or <a target="_blank" href="https://www.benzinga.com/news/large-cap" rel="noreferrer noopener">$102 million net of estimated cash</a>.
The deal, which represents an 88% premium to the closing price of $2.66 <a href="https://www.benzinga.com/pressreleases/25/03/b44239452/2seventy-bio-enters-into-definitive-agreement-to-be-acquired-by-bristol-myers-squibb" target="_blank" rel="noreferrer noopener">on March 7, 2025</a>, is expected to close in the second quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43528698/bristol-myers-squibb-warns-near-term-impact-due-to-generics-on-2025-sales-forecast-outlines-2-billion-in-additional-cost-cuts" rel="noreferrer noopener">Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts</a>
In September, the companies discontinued enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma&nbsp;(idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma" rel="noreferrer noopener">stem cell transplant</a>.
&#8220;Consistent with our focus on capital allocation and creating value for all stakeholders, we anticipate this decision will conserve over $80 million in near-term expenditures and accelerate our path to breakeven in 2025,&#8221; said Chip Baird, CEO of 2seventy bio.
In November 2021, 2seventy bio announced its official launch as an independent, publicly traded company from bluebird bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>).
In February, Carlyle Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CG#NYSE">CG</a>) and SK Capital Partners agreed to <a target="_blank" href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal" rel="noreferrer noopener">acquire bluebird bio</a>.
In April 2024, the FDA approved&nbsp;Bristol-Myers and&nbsp;2seventy Bio's&nbsp;Abecma&nbsp;(idecabtagene vicleucel; ide-cel) for adult patients with relapsed or refractory multiple myeloma after two or more&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38114915/fda-approves-bristol-myers2seventy-bios-abecma-for-earlier-use-in-pretreated-blood-cancer-patient" rel="noreferrer noopener">prior lines of therapy</a>.
Price Action: TSVT stock is up 76.4% at $4.9, and BMY stock is down 1.04% at $62.45 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44245475/eaton-strengthens-data-center-strategy-with-14-billion-fibrebond-acquisition" target="_blank" rel="noreferrer noopener">Eaton Strengthens Data Center Strategy With $1.4 Billion Fibrebond Acquisition</a></li>
</ul>
Photo: Shutterstock

Large Cap

TSVT

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

JP Morgan analyst Eric Joseph upgrades bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) from Underweight to Neutral.

Upgrades

JP Morgan Upgrades bluebird bio to Neutral

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 700 points on Friday.
The Dow traded down 1.63% to 43,457.49 while the NASDAQ fell 1.63% to 19,637.11. The S&amp;P 500 also fell, dropping, 1.38% to 6,033.27.
Check This Out: <a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a>
Leading and Lagging Sectors Consumer staples shares jumped by 0.6% on Friday.
In trading on Thursday, consumer discretionary shares fell by 2.7%.
Top Headline
The S&amp;P Global services PMI dipped to 49.7 in February versus 52.9 in the prior month, down from estimates of 53.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) shares shot up 64% to $0.3286 after the company announced a new strategic acquisition agreement.</li>
<li>Shares of Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>)got a boost, surging 49% to $0.2118.</li>
<li>GDEV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEV#NASDAQ">GDEV</a>) shares were also up, gaining 43% to $20.23 after the company announced a one-time special cash dividend of $3.31 per share.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Aspire Biopharma Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares dropped 55% to $2.8000. Aspire Biopharma entered into $3 million senior secured convertible debenture agreement.</li>
<li>Shares of Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) were down 48% to $0.4850.</li>
<li>bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) was down, falling 42% to $4.09. The company announced it agreed to be acquired by Carlyle and SK Capital for a potential total value of up to $9.84 per share.</li>
</ul>
Commodities In commodity news, oil traded down 2.7% to $70.56 while gold traded up 0.1% at $2,957.20.
Silver traded down 1% to $33.140 on Friday, while copper fell 1.4% to $4.5475.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.52%, Germany's DAX 40 fell 0.12% and France's CAC 40 gained 0.39%. Spain's IBEX 35 Index fell 0.12%, while London's FTSE 100 fell 0.04%.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 gaining 0.26%, China's Shanghai Composite Index gaining 0.85%, Hong Kong's Hang Seng Index gaining 3.99% and India's BSE Sensex falling 0.56%.
Economics
<ul>
<li>The U.S. University of Michigan consumer sentiment fell to 64.7 in February compared to a preliminary reading of 67.8.</li>
<li>The year-ahead inflation expectations surged to an over one-year high of 4.3% during February.</li>
<li>U.S. existing home sales fell by 4.9% to an annualized rate of 4.08 million in January, recording the sharpest drop in seven months.</li>
<li>The S&amp;P Global services PMI dipped to 49.7 in February versus 52.9 in the prior month, down from estimates of 53.</li>
<li>The S&amp;P Global manufacturing PMI climbed to 51.6 in February versus 51.2 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43890670/this-unity-software-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-friday">This Unity Software Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

ASBP

BURU

GDEV

MNDR

Dow Tumbles Over 700 Points; US Services PMI Falls In February

Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">and </a><a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">SK Capital Partners</a><a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">.</a>
The agreement, which also includes a team of biotech executives, will see Bluebird Bio&#8217;s stockholders receive $3.00 per share in cash, along with a contingent value right, which could potentially bring the total payout to up to $9.84 per share, depending<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43878541/bluebird-bio-announces-definitive-agreement-to-be-acquired-by-carlyle-and-sk-capital" rel="noreferrer noopener"> on the product portfolio performance.</a>
The acquisition will provide Bluebird Bio with capital to scale its commercial delivery of gene therapies for patients suffering from sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Following the acquisition&#8217;s completion, former Mirati Therapeutics CEO David Meek is expected to take over as Bluebird Bio&#8217;s new CEO.
This strategic acquisition comes after Bluebird Bio&#8217;s financial struggles, including the denial of a priority review voucher by the FDA and mounting challenges that could have led to a loan default.
This strategic acquisition comes after Bluebird Bio&#8217;s challenges, including the denial of a priority review voucher by the FDA and mounting financial&nbsp;issues that could have led to a loan default.
Also Read:<a target="_blank" href="https://www.benzinga.com/tech/25/02/43876492/apples-visual-intelligence-may-come-to-iphone-15-pro-heres-how-it-can-transform-your-camera-with-ai-powered-real-time-search" rel="noreferrer noopener"> Apple&#8217;s Visual Intelligence May Come To iPhone 15 Pro: Here&#8217;s How It Can Transform Your Camera With AI-Powered Real-Time Search</a>
The deal is anticipated to close in the first half of 2025, subject to regulatory approvals and customary closing conditions.
&#8220;For more than a decade, bluebird has been at the forefront of gene therapy, delivering groundbreaking treatments to patients facing life-threatening genetic diseases,&#8221; said Andrew Obenshain, current CEO of Bluebird Bio. &#8220;However, as our financial challenges mounted, it became clear that securing the right strategic partner was critical to maximizing value for our stockholders and ensuring the long-term future of our therapies.&#8221;
Upon completion of the deal, bluebird will become a privately held company, and its shares will no longer be publicly traded.
In addition, Bluebird Bio has entered into amendments to its loan agreement with Hercules Capital to facilitate adequate liquidity to position it to maintain operations through the closing.
Price Action: BLUE shares traded lower by 37.5% to $4.40 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty" target="_blank" rel="noreferrer noopener">Institutional Investors Load Up On Technology And Financial Stocks In Q4 While Reducing Positions In Healthcare Sector Amid Political Uncertainty</a></li>
</ul>
Photo via Shutterstock.

What's Going On With Gene Therapy Company Bluebird Bio Stock Today?

Bluebird Bio shares are trading lower. The company announced it agreed to be acquired by Carlyle and SK Capital for a potential total value of up to $9.84 per share.

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027, for a potential total value of up to $9.84 per share in cash, subject to the tender of a majority of the outstanding shares of bluebird, receipt of applicable regulatory approvals, and other customary closing conditions.

bluebird bio Agrees To Be Acquired By Carlyle And SK Capital For Potential Total Value Of Up To $9.84 Per Share In Cash

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, HUSA, BLUE on Behalf of Shareholders

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE

The Future of Stem Cell Investing: Spotlight on Smaller Innovators

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WBA, IVAC, BLUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Comments

bluebird bio

Noticias

Últimas noticias sobre bluebird bio (NASDAQ:BLUE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL